More articles from Therapy Concepts I: Endocrinology

You have access
Peptide Receptor Radionuclide Therapy (PRRT) in Patients with Progressive Grade 3 Neuroendocrine Neoplasms (NEN)
Jingjing Zhang, Harshad Kulkarni, AVIRAL SINGH, Karin Niepsch, Dirk Mueller and Richard Baum

Journal of Nuclear Medicine May 1, 2019, 60 (supplement 1) 560;
You have access
Possibility of ¹²³I-meta-iodobenzylguanidine (¹²³I-MIBG) as companion diagnostic drug for therapeutic alpha-emitting meta-²¹¹At-astato-benzylguanidine (²¹¹At-MABG)
Keiichiro Yoshinaga, Songji Zhao, Komei Washino, Miho Aoki, Ken-ichi Nishijima, Saki Shimoyama, Naoyuki Ukon, Chengbo Tan, Kohshin Washiyama, Kazuhiro Takahashi, Hiroshi Ito and Tatsuya Higashi

Journal of Nuclear Medicine May 1, 2019, 60 (supplement 1) 563;
You have access
Evaluation of the CCK-2 receptor agonist ¹⁷⁷Lu-PP-F11N for radionuclide therapy of medullary thyroid carcinoma - Final Results of the phase 0 "Lumed" Study.
Christof Rottenburger, Guillaume Nicolas, Lisa McDougall, Felix Kaul, Emanuel Christ, Michal Cachovan, Roger Schibli, Susanne Geistlich, Martin BÃ©hÃ© and Damian Wild

Journal of Nuclear Medicine May 1, 2019, 60 (supplement 1) 561;
You have access
First clinical experience using targeted alpha-emitter therapy with ²¹²Pb-DOTAMTATE (AlphaMedix ^TM) in patients with SSTR(+) neuroendocrine tumors.
Ebrahim Delpassand, Izabela Tworowska, Farah Shanoon, Rodolfo Nunez, Leo Flores II, Ali Muzammil, Tania Stallons, Amal SAIDI and Julien Torgue

Journal of Nuclear Medicine May 1, 2019, 60 (supplement 1) 559;
You have access
Physiologic versus malignant uncinate process uptake on ⁶⁸Ga-DOTA-TATE PET/MRI
C Elias Graybiel and Thomas Hope

Journal of Nuclear Medicine May 1, 2019, 60 (supplement 1) 565;
You have access
Efficacy of 223Radium in radioactive iodine refractory bone metastases from thyroid cancer: Preliminary results of a single arm Phase II trial
Desiree Deandreis, Aline Maillard, Isabelle Borget, Slimane Zerdoud, Claire Bournaud, Laurence Leenhardt, Marie Terroir, Abir Al Ghuzlan, Martin Schlumberger and Sophie Leboulleux

Journal of Nuclear Medicine May 1, 2019, 60 (supplement 1) 562;
You have access
An update on overall survival from a multi-center, open-label, pivotal phase 2b study of AZEDRA® (iobenguane I 131) in patients with iobenguane scan positive locally advanced or metastatic pheochromocytoma/paraganglioma (PPGL)
Daniel Pryma, Bennett Chin, Richard Noto, Joseph Dillon, Lilja Solnes, Jessica Jensen, Tess Lin, Theresa White, Nancy Stambler, Vincent DiPippo, Syed Mahmood, Vivien Wong and Camilo Jimenez

Journal of Nuclear Medicine May 1, 2019, 60 (supplement 1) 564;
You have access
Long-term outcome of Radioiodine Therapy in Brain Metastases from Differentiated Thyroid Cancer- Single Centre Cohort Study
Chandrasekhar Bal, Sanjana Ballal and Madhav Yadav

Journal of Nuclear Medicine May 1, 2019, 60 (supplement 1) 566;
You have access
Long-term Nephrotoxicity After Peptide Receptor Radionuclide Therapy (PRRT): Myth or Reality?
Jingjing Zhang, Harshad Kulkarni, AVIRAL SINGH, Karin Niepsch, Christiane Schuchardt and Richard Baum

Journal of Nuclear Medicine May 1, 2019, 60 (supplement 1) 567;

Main menu

User menu

Search

More articles from Therapy Concepts I: Endocrinology